title: Does earlier HIV RNA suppression provide long-term benefits?
abstract: In the ARTEMIS and TITAN trials of protease inhibitor-based HAART, patients with earlier HIV RNA suppression (HIV RNA <50 copies/ml less than 12 weeks after starting antiretrovirals) had similar rates of long-term HIV RNA undetectability to patients with later HIV RNA suppression (HIV RNA <50 copies/ml after 12-24 weeks). Analyses of seven other large clinical trials also show no consistent correlations between the early dynamics of HIV RNA decline and long-term virological suppression.
authors.affiliation: Chelsea and Westminster Hospital, London UK.
authors.forename: Graeme
authors.initials: G
authors.lastname: Moyle
authors.forename: Ralph
authors.initials: R
authors.lastname: Demasi
authors.forename: Andrew
authors.initials: A
authors.lastname: Hill
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D017326:Clinical Trials, Phase III as Topic; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D012367:RNA, Viral / Q000097:blood*; D016032:Randomized Controlled Trials as Topic
chemical_list: D019380:Anti-HIV Agents; D012367:RNA, Viral